Hybrid graphene oxide as carrier of doxorubicin: cytotoxicity and preliminary in vivo assays against bladder cancer

Autor(es)

Favaro, Wagner J. ^[1] ; de Souza, Joel G. ^[1] ; Ferreira, Luiz A. B. ^[2] ; de Jesus, Marcelo B. ^[2] ; Duran, Marcela ^[1] ; Bockelmann, Petra K. ^[1] ; Bernardes, Juliana S. ^[3] ; Duran, Nelson ^{[1, 4]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Dept Struct & Funct Biol, Lab Urogenital Carcinogenesis & Immunotherapy, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP - Brazil

^[3] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Nanotechnol Natl Lab LNNano, Campinas, SP - Brazil

^[4] Fed Univ ABC UFABC, Nanomed Res Unit NANOMED, Santo Andre, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY; v. 11, n. 2 JUN 2020.
• Citações Web of Science: 0

Resumo

Two types of graphene oxide (GO) hybrids were synthesised for the administration of doxorubicin (DOX, named GO-CO-DOX) and interfering RNA - siRNA (named GO-PEG-PEI/siRNA). These nanomaterials were used for intervention on vascular endothelial growth factor (VEGF) that represents an important strategy to block the formation of new vessels to inhibit cancer progression. For the delivery of DOX, it was incorporated into GO, while for the delivery of siRNA, GO was covalently bonded with the cationic polyethyleneimine (PEI) and then complexed with siRNA. The nanostructures were characterised by attenuated total reflection ATR-FTIR, zeta potential, x-ray photoelectron spectroscopy (XPS), x-ray diffraction (XRD), and transmission electron microscopy (TEM). The cytotoxicity studies with GO-PEG-PEI and GO-PEG-PEI/siRNA systems showed that both formulations have IC50 values of around 100 mu g ml(-1). The systems were administered in vivo to investigate their antitumor effects against non-muscle-invasive bladder cancer (NMIBC) and showed to be promising for the treatment of NMIBC. (AU)

• Processo FAPESP: 14/11154-1 - Desenvolvimento de híbridos de óxido de grafeno como plataforma para o tratamento do câncer de bexiga não-músculo invasivo: interações da imunoterapia com Bacillus Calmette-Guérin, metformina e RNA de interferência
• Beneficiário: Joel Gonçalves de Souza
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado